| Aug.08,2022 |  Interprotein Announced Collaborative Research Agreement with SANWA KAGAKU on Drug Discovery Research for PPI Inhibitor |
| Feb.16,2022 | Interprotein and SPERA PHARMA enter into an agreement for comprehensive
collaboration in small molecule and peptide drug R&D |
| Jan.07,2022 |
Publication of The Research Paper on Drug Repurposing Study for COVID-19 Treatment with Orally Active Drugs |
| Apr.08,2021 |
Interprotein Announces Collaborative Research Agreement with IWAKI SEIYAKU for Anti-COVID-19 Drug Discovery |
| Mar.15,2021 |
LEQUIO PHARMA and Interprotein Announce Collaborative Research Agreement on Potential Assessment of Curcumin and Curcumin Analogs/Derivatives as Anti-COVID-19 Drugs |
| Sept.30,2020 |
Article: Interprotein Corporation (Interprotein) to identify inhibitors for an undisclosed protein-protein interaction (PPI) target in collaboration with Janssen Biotech Inc. |
| Sept.08,2020 |
Article: Interprotein Announces Collaboration with Janssen Biotech, Inc. for Drug Discovery Research Targeting PPI |
| Jun.20,2020 |
Assay Result of Repurposing Drug Candidates for COVID-19 |
| Apr.30,2020 |
Interim Result of Drug Repurposing Examination for COVID-19 |
| Sept.18,2019 |
Publication of the journal including an article written by Hirotsugu KOMATSU, Ken IKEDA, Takeshi TANAKA and Takao MATSUZAKI |
| Aug.26,2019 |
Announcement on the update of introduction article of Interprotein in the “Bio Venture Directory” published by Japan Bioindustry Association (JBA) |
| Aug.20,2019 |
Announcement on the lecture by Masato HOSODA, CEO and President in the EY Life Science Symposium |
| Jul.8,2019 |
Announcement on the lecture by Masato HOSODA, CEO and President in the 59th Workshop of the 169th Committee on Structural Biology using Diffraction Techniques |
| Mar.20,2019 |
Publication of the journal including an article written by Hirotsugu KOMATSU, Takeshi TANAKA, Takao MATSUZAKI |
| Sept.12,2018 |
Introduction of Interprotein Corporation in BenchSci’s expanding list of exceptional Biotech companies engaged in Artificial Intelligence |
| May.17,2018 |
Joint research project “Development of Radioprotection Drug” has won the Osaka City Innovative Creation Grant |
| May.16,2018 |
AI-guided INTENDD®, Interprotein’s AI drug discovery platform based on deep learning of binding structures of small molecules and target proteins, is transitioning into a practical stage |
| Feb.2,2018 |
"Pharmacological activity value prediction system of compound by AI (depth learning)" has been registered as program copyright.
|
| Oct.6,2017 |
Presentation materials are uploded
|
| Oct.6,2017 |
A paragraph on AI-guided INTENDD® has been added.
|
| Oct.5,2017 |
We will be attending BioJapan 2017 from October 11-13 (Wed-Fri).
|
| Oct.4,2017 |
Dr. Takeshi Tanaka, the general manager of Drug Design lab gave a presentation titled "The Contribution of Entropy in Drug-Protein Binding" at the CBI annual meeting 2017 on 3rd October. |
| Oct.3,2017 |
On October 10th, we'll be attending the "European Biotech and Pharma Partnering Conference, Osaka 2017". |
| Sep.21,2017 |
We are now connected with Biocomo(add a banner)!
|
| Aug.21,2017 |
Dr. Takeshi Tanaka, the general manager of Drug Design lab, published an article in the journal of Medical Science Digest.
|
| Jul.18,2017 |
We have renewed our web site! and also started Twitter, please follow us!
|
| Jul.18,2017 |
Dr. Matsuzaki, the head of Drug Design lab, contributed a section to the Encyclopedia of Artificial Intelligence (The Japanese Society for Artificial Intelligence Edition), which was published on July 10, 2017.
|
| Jul.11,2017 |
On July 25th, Masato Hosoda, CEO, will give a presentation at the KANSAI seminar titled “Kansai in the new era opened by AI” hosted by BBTower, Inc.
|
| Jul.6,2017 |
On July 24th, Masato Hosoda, CEO, will give a presentation at a symposium titled “Realization of a society of health and longevity via application of AI and Big-data” hosted by Institution for Biomedical Research and Innovation (IBRI)
|
| Jul.5,2017 |
On July 7th, Masato Hosoda, CEO, will give a presentation at “Mie university - jurisprudence and medical science joint symposium” hosted by Graduate School of Medicine, Mie University
|
| May.30,2017 |
Dr. Matsuzaki, the head of Drug Design Lab, gave a poster presentation titled “True Landscape of Drug-Protein Binding” at JCUP VIII, an annual science meeting held by OpenEye Scientific Software Inc.
|
| Sept.20,2016 |
New York Medical College and Interprotein Announce Research Partnership Agreement on Drug Discovery Research for small molecule PPI Inhibitors
|
| Apr.25,2016 |
Interprotein Corporation and A.I. Squared, Inc. Sign a Joint Research and Development AI Drug Discovery Agreement
|
| Nov.19,2015 |
Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology
|
| Dec.15,2014 |
Adoption of the subject that Interprotein has applied as a subject for A-STEP
|
| Mar.20,2014 |
Participation of Interprotein in the space experiment for generation of high-quality protein crystals in "Kibo"
|
| Nov.25,2013 |
Adoption of conformationally-constrained peptide (MicroAntibody) binding to vascular endothelial growth factor (VEGF) as a subject for A-STEP
|
| Nov.16,2013 |
Dr.Takao Matsuzaki,Head of Drug Design Lab gave a lecture on ASDD 2013-BIT?fs 1st Annual Symposium of Drug Designology 2013.
|
| Sep.2,2013 |
The first result of assessment of small molecule protein-protein interaction (PPI) inhibitors identified by the collaborative research between RaQualia and Interprotein
|
| Apr.19,2013 |
Agreement on molecular design of small molecule protein-protein interaction (PPI) inhibitor between Interprotein Corporation and Takeda Pharmaceutical Company Limited
|
| Feb.1,2013 |
RaQualia and Interprotein Announce Collaborative Research Agreement on Drug Discovery Research for PPI Inhibitors
|
| Jan.30,2013 |
Interprotein made a presentation at the BIO Asia 2013.
|
| Dec.4,2012 |
Adoption of peptide VEGF inhibitor (micro antibody) program as a subject for A-STEP
|
| Nov.22,2012 |
Result of Assessment of Small molecule Protein-Protein Interaction (PPI) inhibitors Designed by Interprotein Corporation
|
| Nov.15,2012 |
Adoption of small molecule IL-6 inhibitor program of Interprotein as a subject for A-STEP
|
| Mar.19,2012 |
Interviews with leading Life Sciences companies: Interprotein, By Venture Valuation
|
| Nov.21,2011 |
Ajinomoto Pharmaceuticals Co., Ltd. and Interprotein Corporation Sign a Joint R&D and Commercialization Agreement
|
| Sep.30,2010 |
Interprotein and LegoChem Biosciences Sign Collaboration Agreement to Develop VEGF Inhibitor to Treat Solid Tumors
|
| Sep.27,2010 |
Collaboration Agreement on Drug Discovery Research between Interprotein Corporation and Ajinomoto Pharmaceuticals Co., Ltd.
|
| Nov.25,2009 |
Interviews with leading Life Sciences companies: Interprotein, By Venture Valuation |
| Nov.21,2008 |
Adoption of Interprotein?fs VEGF project in Super Special Consortia for supporting the development of cutting-edge medical care
|
| Feb.27,2007 |
Evotec and Interprotein Sign Collaboration Agreement to Develop Interleukin 6 Inhibitors to Treat Inflammatory Diseases
|
| Jan.27,2006 |
Exclusive Patent Licensing of Degranulation Inhibiting Mechanism on Allergy-related Cells
|
| Aug.9,2005 |
The announcement of Inter Cyto Nano Science and Dr. Jun Fujita, professor of the Kyoto University?Cagreed on a patent licensing of production yield improvement of recombinant protein
|
